Evidence map›Paper›PMID 33863935›Full record

ArticleScientific reports2021

Establishment and characterization of a new spontaneously immortalized ER

Stefania Nobili, Antonella Mannini, Astrid Parenti, Chiara Raggi, Andrea Lapucci, Giovanna Chiorino, Sara Paccosi, Paola Di Gennaro, Vania Vezzosi, Paolo Romagnoli and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Stefania Nobili *Department of Health Science, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
Antonella Mannini *Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Astrid ParentiDepartment of Health Science, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
Chiara RaggiDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Andrea LapucciDepartment of Health Science, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
Giovanna ChiorinoFondazione Edo ed Elvo Tempia Valenta, Biella, Italy.
Sara PaccosiDepartment of Health Science, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
Paola Di GennaroPlastic and Reconstructive Surgery Unit - Regional Melanoma Referral Center - Tuscan Tumor Institute (ITT), Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy.
Vania VezzosiDepartment Organizational Structure (SOD) of Pathological Histology and Molecular Diagnostics, AOU Careggi, Florence, Italy.
Paolo RomagnoliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Tommaso SusiniDepartment of Health Science, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
Marcella CoronnelloDepartment of Health Science, Section of Clinical Pharmacology and Oncology, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. marcella.coronnello@unifi.it.
University of Florence · ITFondazione Edo ed Elvo Tempia · ITTumour Institute of Tuscany · ITUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive ductal carcinoma (IDC) constitutes the most frequent malignant cancer endangering women's health. In this study, a new spontaneously immortalized breast cancer cell line, DHSF-BR16 cells, was isolated from the primary IDC of a 74-years old female patient, treated with neoadjuvant chemotherapy and disease-free 5-years after adjuvant chemotherapy. Primary breast cancer tissue surgically removed was classified as ER

Indexed as

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneAgedBreast NeoplasmsCarcinoma, DuctalCD24 AntigenCell Line, TumorCell MovementChemotherapy, AdjuvantEpithelial Cell Adhesion MoleculeFemaleHumansHyaluronan ReceptorsIntracellular MembranesKeratin-7CD24 AntigenCD24 protein, humanCD44 protein, humanEPCAM protein, humanEpithelial Cell Adhesion MoleculeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesHyaluronan ReceptorsKeratin-7Keratin-8Receptors, EstrogenReceptors, Progesterone

Identifiers

PMID33863935
PMCPMC8052418
OpenAlexW3153367594

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.